Skip Navigation


JAC Advance Access originally published online on April 14, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/5/1085    most recent
dkg236v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kamiya, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kamiya, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 1085-1089
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

The mechanisms of action of antivirals against hepatitis B virus infection

Naohiro Kamiya*

Research Laboratory IV, Mitsubishi Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan

Keywords: hepatitis B virus, antiviral, review

The first 150 words of the full text of this article appear below.

Although vaccination programmes among neonates in intermediate to high endemic countries have been successful in preventing vertical transmission of hepatitis B virus (HBV), an estimated 350 million persons are still chronically infected with HBV. Although HBV is transmitted in a fashion similar to that of HIV, HBV infection is more prevalent in certain groups, even in developed countries. Interferon-{alpha} is licensed to treat chronic HBV infection but it is effective in only a minority of patients.1 Thus, the therapeutic challenge to effectively treat chronic HBV infection continues, and the past decade has seen the introduction of new therapeutic strategies to HBV infection.

HBV is a small, partially double-stranded DNA virus and a prototype member of the hepadnavirus family. Its 3.2 kb genome possesses four overlapping open reading frames encoding the envelope (pre-S/S), core (precore/core), polymerase and X proteins. Among these hepadnavirus proteins, a single protein contains the enzyme catalysing RNA- . . . [Full Text of this Article]


   Pyrophosphorolysis and resistance
 

   Mutation studies
 

   Protein priming
 

   Novel drug candidates
 

   Acknowledgements
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?